Adaptimmune <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Potential Nasdaq Delisting After Failing to Meet Minimum Bid Price Requirement
Adaptimmune Therapeutics plc has announced a regulatory issue concerning its compliance with Nasdaq's listing rules. The company received a notice from Nasdaq indicating that the minimum bid price of its American Depositary Shares (ADSs) had fallen below $1.00 per share for 30 consecutive business days, prompting an initial compliance period until April 30, 2025. Despite a subsequent extension to October 27, 2025, Adaptimmune was informed on August 14, 2025, that its securities had a closing bid price of $0.10 or less for ten consecutive trading days, placing it under the "Low Priced Stocks Rule." The company intends to request a hearing before the Nasdaq Hearings Panel to present a plan for compliance and seek further extension. During this process, its ADSs will continue to trade on the Nasdaq Capital Market under the symbol "ADAP." There is no assurance that the panel will approve the company's request for continued listing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-011579), on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.